(19) World Intellectual Property Organization

International Bureau



TERE DELL'OCE RECEDE DE COLOR DELL'OCE DE COLOR DELL'OCE DE COLOR DELL'OCE DE COLOR DELL'OCE DE COLOR DE COLOR

(43) International Publication Date 6 January 2005 (06.01.2005)

PCT

(10) International Publication Number WO 2005/000300 A1

- (51) International Patent Classification⁷: A61K 31/427, 31/4192, 31/4196, 31/433, A61P 35/00, 31/12, 19/02, 11/06, 3/10, 17/00, 25/00, 25/28, 37/00
- (21) International Application Number:

PCT/GB2004/002755

- (22) International Filing Date: 24 June 2004 (24.06.2004)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 0315111.5

27 June 2003 (27.06.2003) GB

- (71) Applicants (for all designated States except US): VERNALIS (CAMBRIDGE) LIMITED [GB/GB]; Granta Park, Abington, Cambridge CB1 6GB (GB). CANCER RESEARCH TECHNOLOGY LTD. [GB/GB]; 61 Lincoln's Inn Fields, London WC2A 3PX (GB). THE INSTITUTE OF CANCER RESEARCH [GB/GB]; Royal Cancer Hospital, 123 Old Brompton Road, London SW7 3RP (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): CHEUNG, Kwai, Ming [CN/GB]; The Institute of Cancer Research, Royal Cancer Hospital, 123 Old Brompton Road, London SW7 3RP (GB). DYMOCK, Brian, William [GB/GB]; Vernalis (Cambridge) Limited, Granta Park, Abington, Cambridge CB1 6GB (GB). MACDONALD, Edward [GB/GB]; The Institute of Cancer Research, Royal Cancer Hospital, 123 Old Brompton Road, London SW7 3RP (GB). DRYSDALE, Martin, James [GB/GB]; Vernalis

(Cambridge) Limited, Granta Park, Abington, Cambridge CB1 6GB (GB).


- (74) Agent: WALLS, Alan, James; Vernalis (Cambridge) Limited, Granta Park, Abington, Cambridge CB1 6GB (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED 5-MEMBERED RING COMPOUNDS AND THEIR USE



(57) Abstract: Compound of a compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, in the preparation of a composition for inhibition of HSP90 activity: wherein ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms, for example 1,2,3-triazolyl or a 1,2,4-triazolyl or a tetrazolyl ring; and R₁ R₂ R₃ are as defined in the specification are inhibitors of HSP90 and therefore of use in the treatment of, for example, cancers, viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor; or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie /CJD, Huntingdon's and Alzheimer's disease.

